NHA2 inhibitors might be beneficial in genetic syndromes of arterial hypertension (e.g., Gordon’s syndrome) that lead to increased abundance and activity of WNK-kinases (and subsequently the SPAK-NCC axis) to directly inhibit the increase in WNK-kinase activity before the entire cascade is stimulated. Here, SLC9B2 is linked to Hypertension.